Therapeutic oligonucleotides offer sequence-selective, programmable ways to modulate disease biology, but reaching the right cells outside the liver remains a persistent barrier. This blog introduces AOCs as a strategy for extending targeted delivery to skeletal muscle, heart and brain, where LNPs and GalNAc conjugates have had limited reach. It positions AOCs against monoclonal antibodies and ADCs to clarify what sets the modality apart, and breaks down the three components of an AOC: targeting ligand, linker chemistry and oligonucleotide payload.
Link:
https://isogenica.com/why-antibody-oligonucleotide-conjugates-are-gaining-momentum/